BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 11985054)

  • 1. [How is bone formed and resorbed?-- molecular mechanisms of bone formation and resorption].
    Suda T
    Rinsho Byori; 2002 Mar; 50(3):267-72. PubMed ID: 11985054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel molecular mechanism modulating osteoclast differentiation and function.
    Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Goto M; Mochizuki SI; Tsuda E; Morinaga T; Udagawa N; Takahashi N; Suda T; Higashio K
    Bone; 1999 Jul; 25(1):109-13. PubMed ID: 10423033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D and bone.
    Suda T; Ueno Y; Fujii K; Shinki T
    J Cell Biochem; 2003 Feb; 88(2):259-66. PubMed ID: 12520524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.
    Suda T; Takahashi N; Udagawa N; Jimi E; Gillespie MT; Martin TJ
    Endocr Rev; 1999 Jun; 20(3):345-57. PubMed ID: 10368775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
    Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
    J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
    J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoclast-derived activity in the coupling of bone formation to resorption.
    Martin TJ; Sims NA
    Trends Mol Med; 2005 Feb; 11(2):76-81. PubMed ID: 15694870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.
    Tsukii K; Shima N; Mochizuki S; Yamaguchi K; Kinosaki M; Yano K; Shibata O; Udagawa N; Yasuda H; Suda T; Higashio K
    Biochem Biophys Res Commun; 1998 May; 246(2):337-41. PubMed ID: 9610359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
    J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoblasts and bone formation.
    Caetano-Lopes J; Canhão H; Fonseca JE
    Acta Reumatol Port; 2007; 32(2):103-10. PubMed ID: 17572649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The molecular mechanism of osteoclastic bone resorption and inhibitory drugs for bone resorption].
    Yamamoto Y; Noguchi T; Udagawa N
    Clin Calcium; 2005 Jul; 15(7):11-6. PubMed ID: 15995290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular basis of osteoclast differentiation and activation.
    Suda T; Kobayashi K; Jimi E; Udagawa N; Takahashi N
    Novartis Found Symp; 2001; 232():235-47; discussion 247-50. PubMed ID: 11277084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiopathological basis of bone turnover.
    Masi L; Brandi ML
    Q J Nucl Med; 2001 Mar; 45(1):2-6. PubMed ID: 11456372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts.
    Rifas L; Arackal S; Weitzmann MN
    J Cell Biochem; 2003 Mar; 88(4):650-9. PubMed ID: 12577299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
    Kaji H; Kanatani M; Sugimoto T; Chihara K
    Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin and inflammation.
    Saidenberg Kermanac'h N; Bessis N; Cohen-Solal M; De Vernejoul MC; Boissier MC
    Eur Cytokine Netw; 2002; 13(2):144-53. PubMed ID: 12101070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone remodeling.
    Hadjidakis DJ; Androulakis II
    Ann N Y Acad Sci; 2006 Dec; 1092():385-96. PubMed ID: 17308163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory mechanisms of osteoblast and osteoclast differentiation.
    Katagiri T; Takahashi N
    Oral Dis; 2002 May; 8(3):147-59. PubMed ID: 12108759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.